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PRAXAIR AND THE PTAB’S SHADOW OVER
BIOTECHNOLOGY PATENTS
NORA J. MCGUFFEY*
ABSTRACT
The biotechnology industry is one of the fastest growing fields in research
and development. This may be attributed to the decision in Diamond v.
Chakrabarty, where the Supreme Court held that a biotechnology invention was
patent-eligible subject matter under 35 U.S.C. § 101. However, recent Supreme
Court rulings have left the boundaries of § 101 uncertain, unworkable, and difficult
for biotechnology industries to gain patent protections for their inventions. Before
Congress enacted the AIA in 2011, the courts were the biggest influence on shaping
the doctrine of patent eligible subject matter under § 101. But now with the new
AIA post-grant proceedings, the PTAB plays an influential role in determining
subject-matter eligibility.
Through the new AIA post-grant proceedings, the PTAB has the ability to
hear petitions that challenge the validity of a patent under §§ 101, 102, 103, or
112. But after the recent decision in Praxair Distribution., Inc. v. Mallinckrodt
Hospital Products IP Ltd., the PTAB may now begin exerting too much influence
over the doctrine of § 101. This decision, a case heard in inter partes review,
threatens to stretch the PTAB’s power dangerously thin. Under the AIA, cases
reviewed in inter partes review may not present challenges on patentable subject
matter under § 101. However, in Praxair, the PTAB used parts of a § 101 analysis
to determine that the claims were ineligible subject matter. The Federal Circuit
affirmed the PTAB’s reasoning, suggesting that PTAB may be able to expand the
reach of § 101 and allow petitioners to bring eligibility claims in inter partes
review—where it is statutorily not allowed. Overall, the PTAB’s power over
eligible subject matter makes it easier for applications and patents to be
invalidated under § 101. This could particularly harm biotechnology and
bioscience industries where patent protection is at a disadvantage.
This Note will discuss how the Supreme Court and PTAB have affected the
subject-matter eligibility under § 101 and how this impacts patent rights for
biotechnology innovation. Specifically, this Note will discuss how the PTAB’s
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decision in Praxair has expanded the scope of inter partes review and further added
to the uncertainty of patentable subject matter.
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INTRODUCTION
Biotechnology is one of the fastest growing fields of research. The study
of biotechnology encompasses many different fields of research and development,
including biology, genetics, medicine, and software and technology.
Advancements in biotechnology combine biological mechanisms and technology
to invent new products such as drugs, diagnostic tests, and other pharmaceutical
related inventions.1 The biotechnology industry has produced drugs and vaccines
for cancer, Alzheimer’s disease, Parkinson’s disease, diabetes, AIDS, and others.2
Additionally, biotechnology produces hundreds of diagnostic tests based on the
identification of genetic mutations in human DNA.3 Molecular diagnostics play a
key part in medical research and development because it can identify genetic
mutations in human DNA to show an individual’s predisposition to certain diseases
and conditions.4 Some of the most prominent diagnostic tools identify an
individual’s genetic susceptibility to breast or ovarian cancer and detect pathogens
1

CLAUDE BARFIELD & JOHN E. CALFEE, BIOTECHNOLOGY AND THE PATENT SYSTEM: BALANCING
INNOVATION AND PROPERTY RIGHTS 3–4 (2007).
2
Id. at 4 (discussing the advancement of different biotechnology drugs and vaccines).
3
Id.
4
Id.; see also Jeffrey A. Lefstin, Peter S. Menell, & David O. Taylor, Final Report of the Berkeley
Center for Law & Technology Section 101 Workshop: Addressing Patent Eligibility Changes, 33
BERKELEY TECH. L.J. 551, 582 (2018).
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in the blood supply like streptococcus and HIV.5 Research and development within
the biotechnology industry are important to improve medical treatments,
pharmaceutical products, healthcare costs, and advance other areas of research.6
And the main incentive for biotechnology research and development are
intellectual property rights.7 As such, intellectual property rights are crucial to
ensure that the biotechnology industry continues to make advancements in
innovation.
Biotechnology patents8 encompass a wide range of inventions such as
medical diagnostic test and purified substances like enzymes and proteins.9 One of
the first biotechnology patents recognized was in Diamond v. Chakrabarty. In
Chakrabarty, the Supreme Court held that a patent for genetically modified
bacterium was patentable under 35 U.S.C. § 101.10 Many acknowledge the
Supreme Court’s decision in Chakrabarty as the key factor in sparking interest in
biotechnology innovation.11 The Court paved the way for dramatic advances in life
science and medical research by recognizing that biotechnology inventions
involving genetically modified living organisms are patentable subject matter.12 As
a result, the United States became one of the first countries to secure property rights
in advanced biotechnology inventions.13 The Chakrabarty decision encouraged
large private firms to strengthen their investment in biotechnology research, and
caused the formation of thousands of small firms that would license patented
biotechnology research.14 This made the United States the birthplace of the
biotechnology revolution.15
5

BARFIELD & CALFEE, supra note 1, at 4.
Id. at 3–10 (discussing the impacts that advancement in biotechnology has had over different
industries and fields).
7
See id. at 26 (noting that “patents can motivate new inventions, and/or the commercialization of
inventions that might have been created (but not commercialized) without patent protection, and/or
motivate the efficient coordination of follow-up research”).
8
The United States Patent and Trademark Office classifies biotechnology and organic patent
applications in Technology Center 1600. See Patent Technology Centers Management, U.S. PATENT
& TRADEMARK OFFICE, https://www.uspto.gov/patent/contact-patents/patent-technology-centersmanagement (last visited Feb. 27, 2019).
9
Lefstin et al., supra note 4, at 583.
10
Diamond v. Chakrabarty, 447 U.S. 303 (1980); 35 U.S.C. § 101 (2012).
11
See Kevin Madigan & Adam Mossoff, Turning Gold into Lead: How Patent Eligibility Doctrine
Is Undermining U.S. Leadership in Innovation, 24 GEO. MASON L. REV. 939, 943 (2017); John
Edward Schneider, Microorganisms and the Patent Office: To Deposit or Not to Deposit, That is the
Question, 52 FORDHAM L. REV. 592, 594 (1984) (noting that Chakrabarty “spurred the increased
commercial interest in biotechnology,” and the biotechnology revolution is one of the most important
developments affecting industries in the twentieth century).
12
Madigan & Mossoff, supra note 11, at 943.
13
Id.
14
BARFIELD & CALFEE, supra note 1, at 48.
15
See id. at 24–29 (discussing the important role that patent protection has on biotechnology
innovation); Madigan & Mossoff, supra note 11, at 944.
6
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But under current jurisprudence, patent protection for biotechnology
inventions has been on the decline.16 This is largely because the doctrine of patenteligible subject matter under 35 U.S.C. § 101 is a real mess.17 After the modern
§ 101 cases—Bilski v. Kappos,18 Mayo Collaborative Services. v. Prometheus
Laborites, Inc.,19 Ass’n for Molecular Pathology v. Myriad Genetics,20 and Alice
Corp. Pty. v. CLS Bank International21—the Supreme Court left the boundaries of
subject-matter eligibility uncertain and unworkable. These cases, especially Mayo
and Myriad, considerably eroded patent protection for biotechnology innovation.22
Although the United States Patent and Trademark Office (“USPTO”)
continues to issue patents, the rulings in Mayo and Myriad make it difficult for
inventions in the biotechnology field to gain patent protection.23 This is likely
because the bulk of modern biotechnology inventions stem from varying degrees
the ineligible subject matter, such as laws of nature, natural phenomena, or abstract
ideas.24 Moreover, the Alice-Mayo test contributes to this issue because the test
fails to set clear guidelines between inventions that are eligible subject matter and
inventions that are not.25
After the signing of the American Invents Act (“AIA”) of 2011, the judicial
system is not the only one to blame for § 101’s current state.26 The AIA gives a
16

Lefstin et al., supra note 4, at 561 (noting that “[S]ince Mayo, the number of § 101 invalidity
rulings has skyrocketed, with more than one hundred invalidity determinations per year during the
past two years”).
17
Kristen Osenga, The Problem with PTAB’s Power Over Section 101, 17 CHI.-KENT J. OF INTELL.
PROP. 401, 405 (2018).
18
Bilski v. Kappos, 561 U.S. 593 (2010).
19
Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).
20
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
21
Alice Corp. Pty. v. CLS Bank, Int’l, 573 U.S. 208 (2014).
22
See Lefstin et al., supra note 4, at 583 (stating that “patent protection for diagnostics has
significantly eroded over the past decade due to judicial decisions.”).
23
Id. The USPTO continues to issue patents related to biotechnology inventions despite the
Supreme Court’s ruling. Kate Gaudry et al., Trends in Subject Matter Eligibility For Biotechnology
Inventions, IPWATCHDOG (July 12, 2015), http://www.ipwatchdog.com/2015/07/12/trends-insubject-matter-eligibility-for-biotechnology-inventions/id=59738/.
24
See Shen Lin, The Limits of Biotechnology Inventions in Patent Eligibility, MEDIUM (Oct. 26,
2018), https://medium.com/@shenlin2/the-limits-of-biotechnology-inventions-in-patent-eligibility3fba5450955 (discussing biotechnology and pharmaceutical inventions are likely to fall into a
judicial exception because law surrounding § 101 is vague); Gene Quinn, The Looming Patent
Nightmare Facing the Pharmaceutical Industry, IPWATCHDOG (July 8, 2015), http://www.
ipwatchdog.com/2015/07/08/the-looming-patent-nightmare-facing-the-pharmaceuticalindustry/id=51428/ [hereinafter Looming Patent] (noting that the pharmaceutical industry relies
heavily on computer-aided drug design, which makes those inventions susceptible to being rejected
as ineligible subject matter for relating to an abstract idea).
25
See Lefstin et al., supra note 4, at 593 (noting that application of the Alice-Mayo test’s inventive
concept step for natural law or phenomenon does not provide objective guidance to examiners,
jurists, practitioners, or inventors).
26
Osenga, supra note 17, at 408.
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great deal of power to the USPTO and, in turn, the Patent Trial and Appeal Board
(“PTAB”) and its post-grant proceedings.27 Through the AIA’s post-grant
proceedings, covered business method review (“CBMR”), post-grant review
(“PGR”), and inter partes review (“IPR”), the PTAB has more power and
discretion to shape § 101 doctrine and what it considers patentable subject matter.
Because of modern § 101 Supreme Court cases, the PTAB has been able to
significantly influence the development of subject-matter eligibility.28 As a result,
the PTAB’s ability to determine what constitutes patentable subject matter
increases the power of the USPTO.29
The following discussion describes how the Supreme Court’s
jurisprudence on patentable subject matter under 35 U.S.C. § 101 has shaped
PTAB decision making and, in turn, what this effect means for patent rights in
biotechnology innovation. Part II of this Note will discuss how the Supreme
Court’s modern § 101 cases—Bilski, Mayo, Myriad, and Alice—developed subjectmatter eligibility and influenced patent protection for biotechnology inventions and
industries. Part III will give a brief overview of the PTAB and the basics of each
post-grant proceeding. Part IV will discuss how each post-grant proceeding
interacts with § 101 invalidity challenges by analyzing specific biotechnology
patent cases. Part V will discuss Praxair Distribution., Inc. v. Mallinckrodt
Hospital Products IP Ltd.’s future impact and implications on subject-matter
eligibility under § 101 and future patent protection for the biotechnology industry.
I. THE SUPREME COURT’S DEVELOPMENT OF § 101 SUBJECT-MATTER ELIGIBILITY
The Supreme Court acknowledged that it is the role of Congress, not the
courts, to define the limits of patentability; but once Congress has spoken, it is “the
province and duty of the judicial department to say what the law is.”30 In relation
to patentable subject matter, Congress fulfilled its role by enacting 35 U.S.C. § 101
which states, “[w]hoever invents or discovers any new and useful process,
machine, manufacture, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title.”31 It follows that courts must uphold their constitutional
duty to further determine the limits of patentable subject matter under § 101.32

27

Id. at 405.
Id. at 406.
29
Conor T. Flynn, Here Today, Gone Tomorrow? Post-Grant Review and PTAB Interpretation of
Sec. 101 Subject Matter after Myriad, 11 BUFF. INTELL. PROP. L.J. 1, 26 (2015).
30
Diamond v. Chakrabarty, 447 U.S. 303, 315 (1980) (quoting Marbury v. Madison, 1 Cranch 137,
177 (1803)).
31
35 U.S.C. § 101 (2012) (emphasis added).
32
See Diamond, 447 U.S. at 315.
28
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This section will discuss (1) the modern Supreme Court cases and their
subsequent development of the governing analytical framework for determining
subject-matter eligibility under § 101, and (2) the impact of current jurisprudence
on biotechnology patent protection and innovation.
A. The Supreme Court’s Development of the Judicial Exceptions and
§ 101 Framework
Pursuant to § 101, patent-eligible subject matter is “any new and useful
process, machine, manufacture, or composition of matter.”33 Historically, courts
have given § 101 a broad interpretation to include “anything under the sun that is
made by man.”34 But that does not mean § 101 is limitless.35 The Supreme Court
has “long held that [§ 101] contains an important implicit exception: laws of nature,
natural phenomena and abstracts ideas are not patentable.”36 The Court created
judicial limitations to § 101 reasoning that granting a patent over subject matter
relating to the laws of nature, natural phenomena, or abstract ideas would obstruct
the primary goal of patent law.37
Until 2010, the Supreme Court has taken an expansive interpretation of
what constitutes patentable subject matter under § 101.38 Following this lower
courts essentially reduced the limitations of subject-matter eligibility to whether
the invention related to a useful, concrete and tangible result.39 However, after four
landmark Supreme Court cases, the analysis for subject-matter eligibility requires
a much more stringent approach.
In Bilski v. Kappos, the Court decided the fundamental question for
determining a process claim’s subject-matter eligibility was to ascertain whether
the claim related to “three specific exceptions to § 101’s broad patent-eligibility
principles: laws of nature, physical phenomena, and abstract ideas.”40 The Court
declined to adopt the machine-or-transformation test for determining a process
claim’s subject-matter eligibility.41 The Court held the patent’s claims were
33

35 U.S.C. § 101 (2012).
See Diamond, 447 U.S. at 309.
35
Id.
36
Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 70 (2012); see also Diamond,
447 U.S. at 309; Parker v. Flook, 437 U.S. 584 (1978); Gottschalk v. Benson, 409 U.S. 63, 67 (1972);
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
37
Alice Corp. Pty. Ltd. v. CLS Bank, Int’l, 573 U.S. 208, 216 (2014) (“Monopolization of those
tools through the grant of a patent might tend to impede innovation more than it would tend to
promote it, thereby thwarting the primary object of the patent laws.”).
38
John M. Golden, Flook Says One Thing, Diehr Says Another: A Need for Housecleaning in the
Law of Patentable Subject Matter, 82 GEO. WASH. L. REV. 1765, 1767 (2014).
39
Id. at 1768.
40
Bilski v. Kappos, 561 U.S. 593, 601 (2010).
41
Id. at 3226–27. The machine-or-transformation is one way to show that process claim relating to
an abstract idea or law of nature is patentable subject matter if the process is linked to a machine or
34
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ineligible subject matter and, therefore, unpatentable because the claims described
the basic concept of hedging, or protecting against risk which was nothing more
than an abstract idea.42 The Court went further in Mayo Collaborative Services v.
Prometheus Laboratories, Inc., when it held patent claims directed to the
personalized process for administering drug doses were unpatentable under § 101
because they claimed the underlying laws of nature.43 The Court reasoned that if a
law of nature was not patent eligible, then neither was a process that recited the law
of nature, unless the process had an additional feature which made the process
significantly more than the natural law alone.44 Additionally, in Ass’n for
Molecular Pathology v. Myriad Genetics, the patent claimed the isolated DNA
coding for both BRCA1 and BRCA2 and their synthetic sequence.45 The Court held
naturally occurring DNA was a product of nature and not patent eligible under
§ 101 simply because it was isolated.46 But the Court held that synthetically created
DNA (“cDNA”) was not naturally occurring and thus, eligible subject matter.47
Furthermore, the Court noted “ground breaking, innovative, or even brilliant
discoveries does not by itself satisfy the § 101 inquiry.”48
Lastly, in Alice Corp. Pty. v. CLS Bank International, the Court concluded
that specific claims for a computer-implemented scheme for mitigating settlement
risk were unpatentable because they “added nothing of substance to the underlying
abstract idea.”49 However, the Court acknowledged that “[a]t some level all
inventions . . . embody, use, reflect, upon, or apply laws of nature, natural
phenomena, or abstract ideas.”50 An invention is not always patent ineligible
merely because it includes one of the judicial exception.51 Thus, when an invention
includes one of the judicial exceptions, courts must distinguish between patents
that claim an ineligible concept and patents that integrate the ineligible concept into
something more, thereby becoming patent eligible.52 From these four cases, the
Court developed a systematic approach—now known as the Alice-Mayo two-step
test—to determine subject-matter eligibility under § 101:

transforms the object. Id. If the machine-or-transformation was the sole test for determining subjectmatter eligibility, it would make patent protection for diagnostic medicine techniques uncertain. Id.
42
Id. at 611.
43
See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 71–73 (2012).
44
Id. at 71–72.
45
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 583–84 (2013).
Mutations in BRCA genes are commonly linked to breast cancer. Id. at 582–83.
46
Id. at 580.
47
Id.
48
Id. at 591.
49
Alice Corp. Pty. Ltd. v. CLS Bank, Int’l, 573 U.S. 208, 212 (2014).
50
Id. at 217 (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 71 (2012))
(internal quotations omitted).
51
Id.
52
Id.
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First, we determine whether the claims at issue are directed to one
of those patent-ineligible concepts. If so, we then ask, what else is
there in the claims before us? To answer that question, we consider
the elements of each claim both individually and as an ordered
combination to determine whether the additional elements
transform the nature of the claim into a patent-eligible application.
We have described step two of this analysis as a search for an
inventive concept—i.e., an element or combination of elements
that is sufficient to ensure that the patent in practice amounts to
significantly more than a patent upon the ineligible concept itself.53
From this, the Alice-Mayo two-step test can be summarized in the
following two questions:
(1) Does the patent claim relate to an abstract idea, law of nature,
or natural phenomena?
(2) If so, does the patent claim an element or combination that is
significantly more than an ineligible concept (i.e., an inventive
concept)?54
In Alice, the Court was clear that this framework should apply to all judicial
exceptions and all types of claims.55 But this judicial framework has not been kind
to biotechnology industries.56
B. The Repercussions of the Alice-Mayo Two-Step Test
The USPTO developed guidelines based on the Supreme Court holdings in
Bilski, Mayo, Myriad, and Alice.57 The USPTO synthesized the Alice-Mayo twostep into a flow chart and added it into the Manual of Patent Examining Procedure
to help practitioners and examiners.58 However, many criticize the Alice-Mayo
two-step test for being difficult to apply consistently and varying substantially

53

Id. at 217–18 (internal citations omitted).
See U.S. PATENT & TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE, 2100-16
(U.S. Pat. and Trademark Off. (2018)) [hereinafter MPEP].
55
Id.
56
See Naira R. Simmons, Why the Supreme Court Should Use Ariosa v. Sequenom to Provide
Further Guidance on 35 U.S.C. § 101 Patent Eligibility, 16 CHI.-KENT J. INTELL. PROP. 112, 130
(2016).
57
Following any important or groundbreaking case that adds or clarifies the Alice-Mayo two-step
the USPTO will post additional guidelines on their website for examiners and practitioners to use.
See U.S. PATENT & TRADEMARK OFFICE, SUBJECT MATTER ELIGIBILITY: EXAMINATION GUIDANCE
(Jan. 10, 2019, 10:59 AM), https://www.uspto.gov/patent/laws-and-regulations/examinationpolicy/subject-matter-eligibility.
58
MPEP, supra note 54.
54
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between examiners and administrative judges.59 This variation affects patent
prosecution because examiners and administrative judges could reach completely
different outcomes under § 101—eligible and not eligible—for the same set of
claims.60
These Supreme Court rulings—particularly Mayo—significantly impacted
patent protection for biotechnology inventions.61 One report shows that before
Mayo, the USPTO and courts rarely rejected patent applications for ineligible
subject matter; but after Mayo, the number of subject-matter rejections
skyrocketed.62 For example, in Ariosa Diagnostics, Inc. v. Sequenom, Inc., the
Federal Circuit—relying on Mayo—held that a diagnostic test that created an
alternative for prenatal diagnosis of fetal DNA was not patentable subject matter
under § 101.63
The invention in Ariosa revolved around the discovery of cell-free fetal
DNA (“cffDNA”) in maternal plasma and serum.64 cffDNA is the fetal DNA that
circulates freely in the bloodstream of a pregnant woman.65 The patent did not
claim the cffDNA, but claimed the method of using it.66 The method involved
detecting small amounts of paternally inherited cffDNA in maternal plasma or
serum to determine certain fetal characteristics, like gender.67 Following the AliceMayo two-step framework, the Court found that the method claims related to the
naturally occurring phenomena, the cffDNA.68 But the method claims failed the
Mayo’s second step because they “[did] not result in an inventive concept that
transform[ed] the natural phenomenon of cffDNA into a patentable invention.”69
Thus, the Court held the invention unpatentable under § 101 for ineligible subject
matter.70
59

Lefstin et al., supra note 4, at 589.
Id.
61
See Simmons, supra note 56, at 130 (“Ariosa v. Sequenom is a case that clearly illustrate why
the newly created judicial framework fails to protect many inventions in biotechnology.”); Lefstin
et al., supra note 4, at 588 (discussing that patent invalidity rates for § 101 have been the most
dramatic for covered business method and gaming patents, but § 101 invalidity rates are high among
biotechnology and agriculture); Madigan & Mossoff, supra note 11, at 948–49 (noting that the
pharmaceutical innovation struggles to gain patent protection because of their high invalidation
rates).
62
Lefstin et al., supra note 4, at 561, 576.
63
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371,1378 (Fed. Cir. 2015).
64
Id. at 1373.
65
Id.; see also Robert Bock & Meredith Daly, Fetal DNA Sequencing Potentially Could Reduce
Need For Invasive Prenatal Diagnostic Procedures, NAT’L INST. HEALTH (Aug. 1, 2018),
https://www.nih.gov/news-events/news-releases/fetal-dna-sequencing-potentially-could-reduceneed-invasive-prenatal-diagnostic-procedures.
66
Ariosa Diagnostics, Inc., 788 F.3d at 1373.
67
Id.
68
Id. at 1376.
69
Id.
70
Id. at 1380.
60
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The Federal Circuit later denied the petition for a rehearing en banc.71
Circuit Judge Lourie reasoned the petitions denial was based on the precedent of
Mayo because there was no principled basis to distinguish the two cases.72
However, Judge Lourie noted that because of the Supreme Court’s ruling in Bilski,
Mayo, Myriad, and Alice, medical inventions (i.e., diagnostic inventions) could be
at risk of losing patent protection.73 Judge Lourie cautioned that “a crisis of patent
law and medical innovation may be upon us.”74 Other circuit justices, like Circuit
Judge Dyk, shared similar concerns:
I share the concerns of some of my colleagues that a too restrictive
test for patent eligibility under 35 U.S.C. § 101 with respect to laws
of nature (reflected in some of the language in Mayo) may
discourage development and disclosure of new diagnostic and
therapeutic methods in the life sciences, which are often driven by
discovery of new natural laws and phenomena.75
Unfortunately, the Supreme Court implicitly affirmed the Mayo ruling when it
denied the petition for a writ of certiorari in Sequenom Inc. v. Ariosa Diagnostics,
Inc.76—a case that many hoped would clarify what the Supreme Court regarded as
patentable subject matter.77 But Ariosa clearly demonstrates that the current § 101
test severely impacts future patent protection for biotechnology and medical
innovation.
Some commentators noted that the Alice-Mayo two-step test may prevent
potentially lifesaving treatments and antibiotics from patent protection because
they do not conform to the Supreme Court’s definition of eligible subject matter78
(i.e., the inventions relate to a law of nature, natural phenomena, or abstract idea).
If these advancements fail to gain patent protection, an alternative is to seek

71
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 809 F.3d 1282, 1284 (Fed. Cir. 2015) (denying
hearing en banc).
72
Id. at 1284 (Lourie, J., concurring).
73
Id. at 1285 (Lourie, J., concurring).
74
Id.
75
Id. at 1287 (Dyk, J., concurring).
76
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), cert. denied, 136 S.
Ct. 2511 (2016).
77
Lefstin et al., supra note 4, at 557. Notably, the Court’s denial signals that it is inclined to address
the serious challenges created by recent § 101 jurisprudence, thereby leaving patent law with the
Alice-Mayo two-step test. Id. at 562.
78
See Simmons, supra note 56, at 131 (noting that inventions that relate to a judicial exception
“may well be deserving of patent protection,” like prenatal tests that diagnosis possible birth defects
without intrusive means); Lin, supra note 24 (discussing that a bulk of biotechnology and
pharmaceutical innovation are extremely useful and have potentially lifesaving qualities but get
rejected because they related to one or more judicial exceptions); Gaudry et al., supra note 23
(showing an increase in § 101 rejections from 2012 pre-Mayo to February 2015).
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property protection under trade secrets.79 However, trade secret protection for
biotechnology can be hard to maintain because these technologies and diagnostic
tools need to be fully disclosed to the public during the regulatory approval
process.80 For example, biotechnology companies that develop medical diagnostic
tools must publish most of their research in journals to become eligible for financial
reimbursement.81
Others noted that post-Myriad and Mayo, biotechnology industries have
experienced a decrease in patent protection.82 This lowers the possibilities for
biotechnology research to attract investors and possible funding to biotechnology
industries.83 Investors are not interested in investing in Industries where it is
difficult to gain patent protection are unattractive to investors. Patents help
investors remain competitive in the market.84 Patent protection also allows
investors to enforce their property right against potential infringers. Moreover,
biotechnology companies rely on investment funding to survive, and in turn, rely
on strong patent protection.85 Consequently, biotechnology industries with weak or
no patent protection will receive less funding for research and development. The
lack of investment in biotechnology research and development will limit future
advances in the field,86 which would not only affect companies but prevent people
from receiving the benefits of biotechnology innovation. Examples of scientific
research that are experiencing funding difficulties as a result of § 101 standards
are: “cytotoxins derived from sea organisms (purified natural products) that could
be used in treating tissue sarcoma; genes relating to particular genetic mutations;
and snake toxins used for treating multiple sclerosis.”87 Because of the Supreme
Court’s uncertain and unworkable guidance in Bilski, Mayo, Myriad, and Alice,
patent rights for biotechnology industries have been negatively impacted.88
Overall, this could affect future research and development within the medical,
pharmaceutical, and other biotechnology industries.

79

Simmons, supra note 56, at 126.
Id.
81
Lefstin et al., supra note 4, at 583.
82
Id.
83
Id. at 583–84; Gene Quinn, Did the Supreme Court Intentionally Destroy the U.S. Patent
System?, IPWATCHDOG (May 22, 2018), http://www.ipwatchdog.com/2018/05/22/did-the-supremecourt-intentionally-destroy-the-u-s-patent-system/id=97514/ [hereinafter Supreme Court].
84
See Supreme Court, supra note 83; Should You Invest in Patent Protection?, COOLEYGO,
https://www.cooleygo.com/should-you-invest-in-patent-protection/ (last visited Nov. 4, 2019).
85
See BARFIELD & CALFEE, supra note 1, at 30.
86
Lefstin et al., supra note 4, at 583–84.
87
Id.
88
See id. at 582–584; Osenga, supra note 17, at 410.
80

5. [FINAL PROOF] MCGUFFEY_PRAXAIR_AND_THE_PTAB.DOCX (DO NOT DELETE)

122

UC Davis Business Law Journal

3/8/20 1:01 PM

[Vol. 20

II. THE PATENT TRIALS AND APPEALS BOARD
Under the AIA, 89 Congress conferred a significant amount of power to the
USPTO by creating the PTAB, which replaced the former Patent Board of
Interferences. This section will briefly discuss (1) the structure of the PTAB, and
(2) the general mechanics of the post-grant proceeding.
Because the U.S. patent system had become complex, Congress created the
AIA to “establish a more efficient and streamlined patent system that [would]
improve patent quality and limit unnecessary and counterproductive litigation
costs.”90 The PTAB has a panel of three judges who are selected based on their area
of expertise needed in the science or technology field.91 The AIA requires PTAB
judges to be “persons of competent legal knowledge and scientific ability,”92 which
helps them understand the complexities of patents and its subject matter.
Additionally, knowledgeable judges can answer legal questions from the
perspective of a ‘person of ordinary skill in the art.’93
The AIA granted the PTAB the power to hear three new post-grant
proceedings: IPR,94 CMBR,95 and PGR.96 These new proceedings provide a costeffective alternative to litigation for patent validity challenges.97 These post-grant
proceedings have “significantly strengthened the U.S. system for administrative
review of patent validity,”98 and give the USPTO a better forum to correct the errors
in “bad patents” from the initial examination process. Before the AIA, it was
common for a defendant to assert an invalidity claim as a defense to infringement,
but these post-grant proceedings allow potential defendants to preemptively
invalidate a patent.99

89

Leahy-Smith America Invents Act, Pub. L. No. 112–29, 125 Stat. 284 (2011) (codified as
amended in scattered sections of 35 U.S.C.) [hereinafter AIA].
90
Flynn, supra note 29, at 7 (quoting Mark Consilvio & Jonathan R.K. Stroud, Unraveling the
U.S.P.T.O.’s Tangled Web: An Empirical Analysis of the Complex World of Post-Issuance Patent
Proceedings, 21 J. INTELL. PROP. L. 33, 43–45 (2013)).
91
Stuart Minor Benjamin & Arti K. Rai, Administrative Power in the Era of Patent Stare Decisis,
65 DUKE L.J. 1563, 1569 (2016).
92
AIA § 7(a); 35 U.S.C. § 6(a) (2012).
93
A person of ordinary skill in the art (“PHOSITA”) is similar to a “reasonable person” in torts
law. However, because of the complex and technical nature of patent law, a PHOSITA is specific to
that inventions technical field of study. See Nainia & Jasmeet Gulati, Knowledge/Skill Standards of
“Person Skilled in Art”: A Concern Less Visited, 17 J.MARSHALL REV. INTELL. PROP. L. 588, 601602 (2018).
94
AIA § 6(a); 35 U.S.C. § 311(a).
95
AIA § 18; 35 U.S.C. § 321 (note).
96
AIA § 6(d); 35 U.S.C. § 321.
97
Flynn, supra note 29, at 8.
98
Saurabh Vishnubhakat et al., Strategic Decision Making in Dual PTAB and District Court
Proceedings, 31 BERKELEY TECH. L.J. 45, 58 (2016).
99
Id. at 48.
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Generally, each post-grant proceeding follows the same process. First, a
person—not the patent holder—submits a petition to the USPTO to institute a postgrant proceeding.100 The petition must challenge the patent’s validity under either
§§ 101, 102, 103, or 112. However, the AIA limits what each post-grant proceeding
may hear. IPR allows challenges based on § 102 novelty or § 103 obviousness,101
CMBR allows challenges on any ground of invalidity, but only for certain types of
business method patents,102 and PGR allows challenges on any ground of invalidity
for patents filed on or after March 16, 2013.103 Second, the panel of judges sitting
on the PTAB decides whether the petition satisfies the statutory threshold to
institute the proceeding. To initiate an IPR, the petition must show there is a
“reasonable likelihood that the petitioner would prevail with respect to at least 1 of
the claims challenged in the petition.”104 For CBMR and PGR, a petition must show
that it is “more likely than not that at least 1 of the claims challenged in the petition
is unpatentable.”105 If the panel decides that the petition satisfies the required
standard, it will initiate a review of the patent.106 The PTAB’s decision to institute
a proceeding is final and not appealable.107 Once initiated, the PTAB tends to make
its final decision within a year.108 Although the goal of the PTAB and post-grant
proceedings was to improve the patent system, these new AIA additions have
created more confusion and complications for subject-matter eligibility.
III. CHALLENGING § 101 SUBJECT-MATTER ELIGIBILITY IN POST-GRANT
PROCEEDINGS
Before the AIA, courts were one of the biggest influences on shaping the
doctrine of patent eligible subject matter under 35 U.S.C. § 101. Through the scope
of the post-grant proceedings, Congress gave the PTAB, and inherently the
USPTO, the power to answer pivotal questions of law. Explicitly through CBMR
and PGR, the PTAB has significant power and discretion to determine patentable
subject matter under § 101,109 an area of patent law that has previously been left
for the courts to interpret. Many scholars attribute § 101 uncertainty to the Supreme
Court’s decisions in Bilski, Mayo, Myriad, and Alice; however, now the Supreme

100

See 35 U.S.C. § 311 (providing for IPR); id. § 321(a) (providing for PGR); id. § 321(note)
(providing for CMBR).
101
Id. § 311(b).
102
Id. § 321(a)(1) (note).
103
Id. § 321(b).
104
Id. § 314(a).
105
Id. § 324(a).
106
Id. §§ 314(a), 324(a).
107
Id. §§ 314(e), 324(d); see also Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131 (2016).
108
35 U.S.C. §§ 316(a), 326(a)(11).
109
Flynn, supra note 29, at 3.
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Court may not be the only one to blame.110 The PTAB’s broad power over § 101
allows the USPTO to expand or shrink the scope of patentable subject matter.111
This is not the only way the PTAB has affected § 101.
This section will examine how each post-grant proceeding has interacted
with § 101 invalidity challenges relating to a biotechnology patent. Each section
will briefly discuss how each decision affects subject-matter eligibility under § 101
and any future implications the decision may have on patent protection for
biotechnology innovation.
A. Covered Business Method Review
Within the CBMR, the PTAB has been known to be very “aggressive,
particularly with respect to its interpretation of section 101.”112 This is likely
because the USPTO has a large amount of discretion in determining what patents
are subject-matter eligible for a CBMR.113 Unlike IPR or PGR, “a person may not
file a petition for a [CBMR] . . . unless the person or the person’s real party in
interest or privy has been sued for infringement of the patent or has been charged
with infringement under that patent.”114 Another key distinction is that CBMRs
only apply to covered business method patents,115 which the AIA defines in
§ 18(d)(1):
The term ‘covered business method patent’ means a patent that
claims a method or corresponding apparatus for performing data
processing or other operations used in the practice, administration,
or management of a financial product or service, except that the
term does not include patents for technological inventions.116
In addition to this broad definition, the AIA directs the USPTO to further
define “technological invention.”117 The USPTO decides “whether the claimed
subject matter as a whole recites a technological feature that is novel and unobvious
over the prior art; and solves a technical problem using a technical solution.”118
This broad definition of “technological invention” gives the USPTO a fair amount
of discretion in determining the subject matter that is eligible for instituting a
110

Osenga, supra note 17, at 405–06 (discussing that the PTAB should share the blame for the
confusion of § 101).
111
Id. at 407.
112
Benjamin & Rai, supra note 91, at 1577.
113
Id. at 1573.
114
AIA § 18(a)(1)(B) (2011).
115
Id. (stating that the “Director shall issue regulations establishing and implementing a transitional
post-grant review proceeding for review of the validity of covered business method patents”).
116
Id. § 18(d)(1).
117
Benjamin & Rai, supra note 91, at 1573.
118
Id. at 1576 (quoting 37 C.F.R. § 42.301(b)).
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CMBR.119 Typically, CBM reviews are limited to patents that are “financial in
nature,” “incidental to financial activity,” or “complementary to financial
activity.”120 In the past, a majority of the CBMR petitions challenged claims on
subject-matter eligibility.121
Although most biotechnology uses software in research and development,
the PTAB generally does not institute CBMR petitions challenging biotechnology
or medical patents122 because they are not a “financial product or service.”123 For
example, in Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. and
Roxane Laboratories, Inc. v. Jazz Pharmaceuticals, Inc., the PTAB declined to
institute a CBMR because the petitioner failed to show that the claim language
recited a method involving the movement of money or credit in exchange for a
product or service.124 In Amneal Pharmaceuticals, the patent related to a “method
for controlling access to a sensitive prescription drug prone to potential abuse or
diversion, by utilizing a central pharmacy and database to track all prescriptions
for the sensitive drug.”125 In Roxane Laboratories, the patent related to a “method
for treating a patient with a sensitive prescription drug and controlling access to the
sensitive prescription drug, which is prone to potential abuse, misuse, or diversion,
by utilizing a central pharmacy and database to track all prescriptions for the
sensitive drug.”126 Because the PTAB held that the patents were not subject-matter
eligible for a CBMR, it could not institute the proceeding to determine the patents’
validity.
The PTAB has a fair amount of discretion on the subject-matter eligibility
for covered business method patents. However, Amneal Pharmaceuticals and
Roxane Laboratories suggest that the PTAB has not found a way to expand the
definition of a “technological invention” to encompass biotechnology subject
matter. Thus, within the scope of CBMR, it is unlikely that the PTAB will have a
significant impact on patent protection for biotechnology innovation.

119

Id.
Marshall Gerstein, For CBM Standing, Is “Incidental To” a Financial Produce Service
Enough?, PTABWATCH (July 7, 2016), https://www.ptabwatch.com/2016/07/for-cbm-standing-isincidental-to-a-financial-product-or-service-enough/.
121
Vishnubhakat et al., supra note 98, at 67.
122
Id. at 92.
123
AIA § 18(d)(1) (2011).
124
Denying Institution of Covered Business Method Review of CBM2014-00149, 150, 151, 153,
PTAB TRIAL BLOG (Jan. 26, 2015), http://ptabtrialblog.com/denying-institution-covered-businessmethod-review-cbm2014-00149-150-151-153/; Denying Institution CMB2014-00161, 175, PTAB
TRIAL BLOG (April 15, 2015), http://ptabtrialblog.com/denying-institution-cbm2014-00161-175/.
125
Amneal Pharms., LLC v. Jazz Pharms., Inc., No. CBM2014-00149/150/151/153, slip op. at 4
(P.T.A.B. Jan. 13, 2015).
126
Roxane Labs., Inc. v. Jazz Pharms., Inc., No. CBM2014-00161/175, slip op. (P.T.A.B. Feb. 9,
2015), https://e-foia.uspto.gov/Foia/RetrievePdf?system=PRPS&flNm=CBM2014-00175_14.
120
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B. Post-Grant Review
PGR may be the most powerful proceeding for invalidating patents.127
PGR’s scope is the broadest of any other post-grant proceeding128 because a
petitioner ”may request to cancel as unpatentable one or more claims of a patent
on any ground.”129 This includes novelty, obviousness, utility, indefiniteness,
written description, enablement, and most importantly, for this Note’s purpose,
subject-matter eligibility. Unlike CBMR, PGR does not limit a petitioner to
business method patents. But a major limitation for PGRs is petitioners may only
challenge patents that issue under the AIA’s first-to-file regime (i.e., have an
effective filing date on or after March 16, 2013).130
Since the Supreme Court’s ruling in Bilski, Mayo, Myriad, and Alice,
petitioners have been challenging patents on the basis of subject-matter eligibility
under § 101. In American Simmental Ass’n v. Leachman Cattle of Colorado, LLC,
one of PGR’s first final written decisions, the PTAB invalidated a patent under
§§ 101 and 103. The patent “relate[d] generally to genetic quality and relative
market value of livestock.”131 The patent specifically disclosed embodiments of the
invention that facilitated “an owner or potential buyer of one or more sale groups
of livestock to evaluate the relative market value of the sale groups based on
predictions derived from genetic merit estimates of the herd.”132 With respect to
§ 101, the PTAB followed the Alice-Mayo two-step.133 First, the PTAB found that
the claims were directed to the fundamental concept of “‘determining an animal’s
relative economic value based on its genetic and physical traits,’ and that such a
fundamental concept is a patent ineligible abstract idea.”134 After determining that
the claims were directed to an abstract idea, the PTAB found that “all computer
recitations in the challenged claims [were] recitations to generic computer
hardware used in a conventional manner, which [were] insufficient to impart
patentability under Alice.” Following the Alice-Mayo framework, the PTAB held
the claims were invalid because they were not patentable subject matter.135

127

Flynn, supra note 29, at 8.
Id. at 9.
129
35 U.S.C. § 321(b) (2012) (emphasis added).
130
Flynn, supra note 29, at 10; see also U.S. PATENT & TRADEMARK OFFICE, MAJOR DIFFERENCES
BETWEEN IPR, PGR, AND CBM, http://www.uspto.gov/sites/default/files/ip/boards/bpai/aia_trial_
comparison_chart.pptx (last visited Sept. 15, 2018) [hereinafter MAJOR DIFFERENCES BETWEEN IPR,
PGR, AND CBM].
131
Am. Simmental Ass’n v. Leachman Cattle of Colo., LLC, No. PGR2015-00005, 2016
WL326807 *2 (P.T.A.B. June 13, 2016).
132
Id. at 3.
133
Id. at 21.
134
Id. at 13.
135
Id. at 21 (holding that the PTAB was unpersuaded that the “problem, or its solution, involves
or requires anything computer-related”).
128
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Deciding a petition that challenges subject-matter eligibility, the PTAB
must apply the Alice-Mayo framework laid out by the Supreme Court. Because
PGR is relatively new and can only hear patents that issued under the AIA, there
are fewer petitions than other post-grant proceedings.136 Because there are less
filings, it will take time to see PGR’s true effect on § 101, specifically in technology
areas where issuing patents take longer.137 Furthermore, because the PTAB may
initiate a PGR petition if it “raises a novel or unsettled legal question that is
important to other patents or patent applications,”138 the PTAB has more discretion
to either “shrink or expand” the scope of what is patentable subject matter under
§ 101.139 This is true particularly in technology areas that are evolving at a fast
rate—such as biotechnology and bioscience—because it is no secret that many in
the patent community want to expand the scope of patentable subject matter.140 As
a result, the PTAB, through the venue of PGR, will soon become a crucial
institution for shaping the doctrine of § 101. Currently, PGR has not allowed the
PTAB to change what subject matter is patent eligible.
C. Inter Partes Review
IPR examines patents issued under either the pre-AIA’s first-to-invent or
AIA’s first-to-file regime.141 Petitions in IPR may challenge patents only under
§ 102 novelty and § 103 nonobviousness, and only on the basis of prior art
consisting of patents or printed publications.142 IPR proceedings do not have the
authority to hear petitions that challenge patents under § 101 subject-matter
eligibility.143 However, in a recent case, the PTAB found a way to get around this
limitation by using the printed matter doctrine.
The printed matter doctrine provides that: “[c]laim limitations directed to
printed matter are not entitled to patentable weight unless the printed matter is
functionally related to the substrate on which the printed matter is applied.”144
Simplified, the printed matter doctrine can form a two-part test:
(1) Is the claim limitation directed to printed matter?

136

Benjamin & Rai, supra note 91, at 1569.
Flynn, supra note 29, at 10.
138
35 U.S.C. § 324(b) (2012).
139
Flynn, supra note 29, at 4.
140
Id. at 20.
141
See MAJOR DIFFERENCES BETWEEN IPR, PGR, AND CBM, supra note 130; Vishnubhakat et al.,
supra note 98, at 59.
142
35 U.S.C. § 311(b) (2012).
143
Id.
144
Praxair Distrib. v. Mallinckrodt Hosp. Prods. IP Ltd., 890 F.3d 1024, 1031 (Fed. Cir. 2018).
137
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(2) If so, does the printed matter functionally relate to the substrate
on which it is printed?145
Originally, courts applied the printed matter doctrine to encompass literal
printed materials, but under current jurisprudence, printed matter can include any
claims of content information.146 If the printed matter functionally relates to its
substrate, then the claim limitations are considered patentable weight and the
patentability analysis will proceed. Printed matter functionally relates to its
substrate when it interrelates with the rest of the claim so as to produce a new
useful product.147 But if the claim limitations lack a functional relationship, then
they are not given patentable weight because they are not subject-matter eligible
under 35 U.S.C. § 101.148 Likewise, printed matter lacking a functional relationship
to its substrate will not distinguish the invention from the prior art in terms of
patentability.149 While the underlying requirement of the printed matter doctrine is
subject-matter eligibility, courts have traditionally applied this doctrine to the other
patentability requirements—§ 102 novelty, § 103 non-obviousness, and § 112
written description.150
The IPR proceeding Praxair Distribution, Inc. v. Mallinckrodt Hospital
Products IP Ltd. was the first time the PTAB applied the printed matter doctrine in
the history of its establishment. The petitioner, Praxair Distribution, Inc.
(“Praxair”) challenged U.S. Patent 8,846,112 (the “’112 patent”) owned by
Mallinckrodt Hospitals Products IP Ltd. (“Mallinckrodt”).151 The ’112 patent
claimed a method for administering nitric oxide gas to patients with hypoxic
respiratory failure (a condition where oxygen levels in blood are too low), and the
information regarding the harmful side effects for this treatment:152
[T]he ’112 patent [ ] is directed to methods of distributing nitric
oxide gas cylinders for pharmaceutical application . . . The claims
of the ’112 patent generally require supplying a medical provider
145

See Paul E. Dietze & Elizabeth M. Crompton, The Printed Matter Doctrine- Praxair Distrib.,
Inc. v. Mallinckrodt Hosp. Prods. IP Ltd., HAYNESBOONE (May 23, 2018), http://www.haynesboone.
com/Alerts/the-printed-matter-doctrine (discussing the printed matter doctrine as a two-step
process).
146
Praxiar Distrib., 890 F.3d at 1032.
147
Id.; see also In re Gulack, 703 F.2d 1381, 1385 (Fed. Cir. 1883) (finding a functional
relationship between the printed digits on circular band because “the printed matter and the
circularity of the band were interrelated, so as to produce a new product useful for educational and
recreational mathematic purposes.”).
148
Praxiar Distrib., 890 F.3d at 1032.
149
In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004).
150
Praxair Distrib., 890 F.3d at 1032.
151
See Praxair Distrib., Inc. v. Mallinckrodt Hosp. Prods. IP Ltd., No. IPR2015-00529, 2016 WL
3648375 at *1 (P.T.A.B. July 7, 2016).
152
Praxair Distrib., 890 F.3d at 1028.
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with a cylinder of nitric oxide gas and providing the medical
provider with certain prescribing information relating to the
harmful side effects of nitric oxide for certain patients identified in
the INOT22 study.153
The claim limitations at issue for the purpose of this Note are, as the Federal
Circuit labeled them, the “providing information limitation” (from claim 1),154
“evaluating limitation” (from claim 3),155 “recommendation limitation” (from
claim 7),156 and “pharmaceutically acceptable” (from the preambles of claim 1 and
7).157 Applying the printed matter doctrine, “the [PTAB] interpreted the providing
information, evaluating, and recommendation limitations to be ‘either printed
matter or purely mental steps not entitled to patentable weight,’” because those
limitations did not functionally relate to the other claim limitations (its
substrate).158 Overall, the PTAB invalidated the claims as obvious over the
combination of prior art.159 After the final decision, Praxair appealed and
Mallinckrodt cross appealed.160 Mallinckrodt challenged the PTAB’s application
of the printed matter doctrine on claims 1–8 and 10–11 of the ’112 patent.161

153

Id. (internal citations omitted).
The Federal Circuit used this label for referring to the last two “providing information”
limitations of claim 1. Id. at 1029. Claim 1’s providing information limitations read as: “providing
to the medical provider (i) information that a recommended dose of inhaled nitric oxide gas for
treatment of neonates with hypoxic respiratory failure is 20 ppm nitric oxide and (ii) information
that, in patients with preexisting left ventricular dysfunction, inhaled nitric oxide may increase
pulmonary capillary wedge pressure (PCWP), leading to pulmonary edema, the information of (ii)
being sufficient to cause a medical provider considering inhaled nitric oxide treatment for a plurality
of neonatal patients who (a) are suffering from a condition for which inhaled nitric oxide is indicated,
and (b) have preexisting left ventricular dysfunction, to elect to avoid treating one or more of the
plurality of patients with inhaled nitric oxide in order to avoid putting the one or more patients at
risk of pulmonary edema.” Id.
155
Claim 3 depends from claim 1 and “requires determining that a neonatal patient has preexisting
LVD.” Id. Claim 3’s evaluating limitation reads as: “evaluating the potential benefit of treating the
[neonatal patient] with 20 ppm inhaled nitric oxide vs. the potential risk that inhaled nitric oxide
could cause an increase in PCWP leading to pulmonary edema.” Id.
156
Claim 7’s recommendation limitation reads as: “recommendation that, if pulmonary edema
occurs in a patient who has pre-existing [LVD] and is treated with inhaled nitric oxide, the treatment
with inhaled nitric oxide should be discontinued.” Id.
157
Claim 1 and 7’s preambles are “methods of providing pharmaceutically acceptable nitric oxide
gas.” Id. at 1030.
158
Id. (citing Praxair Distrib., Inc. v. Mallinckrodt Hosp. Prods. IP Ltd., No. IPR2015-00529, 2016
WL 3648375 at *9–10 (P.T.A.B. July 7, 2016)).
159
Praxair Distrib., 2016 WL 3648375 at *22. The PTAB found claim 9 to be patentable, but the
Federal Circuit later reversed the decision for claim 9. See Praxair Distrib., 890 F.3d 1024.
160
Praxair Distrib., 890 F.3d. at 1031.
161
Id.
154
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In Praxair, the Federal Circuit agreed that the PTAB properly applied the
printed matter doctrine during claim construction.162 More importantly, the Federal
Circuit agreed that printed matter lacking patentable weight can include claim
limitations directed to mental steps or processes because they capture informational
content.163 The Court noted claims combining limitations into mental steps may be
patentable if the limitations were functionally related to the substrate.164 The Court
reasoned claimed limitations directed to a mental step may capture information that
would be printed matter lacking patentable weight in an obvious analysis.165 For
example, with respect to the evaluating limitation (claim 3), the Court found that it
“[was] directed to a mental step that was also printed matter.”166 Claim 3’s
limitation required “a medical provider to think about the information claimed in
the providing information limitation of claim 1.”167 But the Court noted that simply
“adding an ineligible mental process to ineligible information” still left claim 3
directed to printed matter.168 The Court concluded the evaluating limitation was
invalid under the printed matter doctrine because the claim limitations were not
functionally related to its substrate.169
Additionally, with respect to “pharmaceutically acceptable” claims, the
Court agreed with the PTAB’s construction the term did not create a functional
relationship to its substrate.170 The Court agreed the ordinary meaning of
“pharmaceutically acceptable” referred to the physical condition of the nitric oxide
gas, not the information that may come with it.171 Moreover, the Court agreed and
rejected Mallinckrodt’s argument that construing “pharmaceutically acceptable”
required considering information in the product’s label because a functional
relationship does not exist simply by adding an instruction sheet to the product.172
Therefore, because the claim limitations incorporated printed matter that
did not functionally relate to their substrates, the claims were not eligible subject
162
Id. at 1033 (noting that claim construction is a legal inquiry that the PTAB has the authority to
make) (citing Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996)).
163
Id. (stating that “like the information claimed by printed matter, mental steps or processes are
not patent eligible subject matter”).
164
Id. at 1033.
165
Id.
166
Id.
167
Id.
168
Id. The Federal Circuit noted that to hold any other way would undermine the printed matter
doctrine and render it moot. Id.
169
Id. at 1034.
170
Id. The PTAB construed “pharmaceutically acceptable nitric oxide gas as nitric oxide gas that
[was] suitable for pharmaceutical use.” Id.
171
Id.
172
Id.; see also AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042, 1065 (Fed. Cir. 2010) (holding
that FDA-required instructions did not create functional of a drug); In re Ngai, 367 F.3d 1336, 1339
(Fed. Cir. 2004) (finding no functional relationship between claimed instructions and a diagnostic
kit).
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matter under § 101 nor given any patentable weight in the § 103 analysis.173 The
Federal Circuit affirmed the PTAB’s use of the printed matter doctrine in an IPR
and decision holding claims 1–8 and 10 as obvious.174 However, Judge Newman
in the concurrence criticized and disagreed with the majority’s application of the
printed matter doctrine:
The printed matter doctrine does not apply to unprinted matter…
Mental steps are mental, not printed. The printed matter doctrine is
directed to printed matter, not information and not mental steps.
This ‘doctrine’ is not relevant to the claimed method of
administering nitric oxide to infants with left ventricular
dysfunction. The claimed method warrants analysis in accordance
with the traditional grounds of sections 102, 103, and 112; not as a
newly created category within section 101.175
Judge Newman correctly stated that that this could have been a
straightforward § 103 analysis because the prior art references described the
information claimed in the ’112 patent.176 Judge Newman disagreed with how both
the PTAB and majority removed specific limitations within claims, decided such
limitations were of “no patentable weight,” and reviewed the remaining parts for
patentability.177 Specifically, Judge Newman called out the PTAB and majority for
converting an obviousness-patentability analysis into eligibility analysis under
§ 101—noting that Praxair’s IPR petition was on the ground of obviousness, not
printed matter.178
The role of information in patentability should depend on novelty and nonobviousness as a whole.179 A patent is not ineligible under § 101 simply because it
includes information or a mental component for a step in a process.180 As Judge
Newman accurately noted, the majority did not add any clarity to patent law by
adopting the meaning that both “information” and “mental steps” mean “printed
matter.”181 Judge Newman firmly stated: “Printed matter is not a mental process,
whatever the content.”182 Under the current jurisprudence, the PTAB and
majority’s new printed matter doctrine serves no purpose other than adding to the
uncertainty of patent eligibility183—especially under § 101.
173
174
175
176
177
178
179
180
181
182
183

Praxair Distrib., 890 F.3d. at 1035.
Id.
Id. at 1038 (Newman, J., concurring).
Id. at 1039 (Newman, J., concurring).
Id. at 1041 (Newman, J., concurring).
Id. at 1039–40 (Newman, J., concurring).
Id. at 1040 (Newman, J., concurring).
See id.
Id.
Id. at 1039 (Newman, J., concurring).
Id.
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IV. THE EFFECTS OF PRAXAIR ON PATENT ELIGIBILITY UNDER § 101
While the printed matter doctrine’s underlying rationale is subject-matter
eligibility, courts traditionally applied this doctrine in § 102 novelty and § 103
nonobviousness analysis.184 After the Federal Circuit’s opinion in Praxair, the
printed matter doctrine is intertwined with § 101 subject-matter eligibility
analysis.185 This case is another example showing the PTAB’s significant influence
over patent law—particularly § 101. Praxair allows the PTAB to impact subjectmatter eligibility in three very important ways: (1) the potential scope and power
of future IPR proceedings, (2) the analysis and application of the Alice-Mayo
framework, and (3) the availability and extent of patent protection for
biotechnology and other bioscience industries.
First, using the printed matter doctrine, the PTAB could expand the scope
and power of IPRs to invalidate patents for ineligible subject matter under § 101.
While the AIA supports an IPR petition can challenge claims under §§ 102
and 103,186 the AIA does not explicitly state that those claims must be invalidated
under §§ 102 and 103. In Praxair, the majority distorted a clear § 103 nonobviousness analysis into a quasi-§ 101 eligibility analysis.187 If the patent clearly
was obvious over the prior art, the majority should have left out the printed matter
doctrine and followed the traditional non-obviousness analysis. The majority
invalidated claims because they added ineligible subject matter (mental process or
abstract idea) to ineligible information that was printed matter.188 Praxair may have
a substantial impact on IPR petitions because the Federal Circuit allowed claims
challenged under § 103 to be invalidated under § 101 based on the printed matter
doctrine. This suggests that the PTAB may be able to expand the reach of future
IPRs to invalidate patents under § 101 or, even further, allow petitions that bring
subject-matter eligibility claims. Allowing the printed matter doctrine in IPRs may
give power to the PTAB that Congress did not intend when it created the AIA postgrant proceedings. Additionally, IPR has the capacity to hear more challenges than
the other post-grant proceedings because it has a lower institutional threshold and
can hear patent filed under both the first-to-invent and first-to-file regimes.189
Combining those factors with Praxair’s printed matter doctrine, future IPR
proceedings will have more power and discretion to invalidate patents, thereby
increasing the PTAB’s influence over subject-matter eligibility under § 101.
184

Id. at 1032 (majority opinion).
See id. at 1038 (Newman, J., concurring).
186
See 35 U.S.C. § 311 (b) (2010) (“A petition in an [IPR] may request to cancel as unpatentable
1 or more claims of a patent only on a ground that could be raised under section 102 and 103”).
187
Praxair Distrib., 890 F.3d at 1039 (“It is note-worthy that Praxair’s petition for inter partes
review was on the ground of obviousness, not printed matter.”) (Newman, J., concurring).
188
Id. at 1033 (majority opinion).
189
See MAJOR DIFFERENCES BETWEEN IPR, PGR, AND CBM, supra note 130.
185
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Second, with the help of the Federal Circuit, the PTAB incorporated the
printed matter doctrine into the Alice-Mayo two-step test. The PTAB addresses
§ 101 issues in different forums, like ex parte appeals.190 This gives the PTAB
many opportunities to develop the law surrounding subject-matter eligibility.191
Since the Federal Circuit’s opinion, the PTAB cited Praxair about fifteen times in
different ex parte appeals.192 From those cases, seven cases cite and discuss
Praxair’s use of the printed matter doctrine to determine whether the application
is invalid under § 101.193 In each case the PTAB affirmed examiners’ § 101
rejections for patent applications because the claims were directed to printed matter
that were not patent eligible subject matter.194 As a result, these cases show that
examiners and the PTAB have incorporated the printed matter doctrine into the
Alice-Mayo framework. The PTAB’s application of the printed matter doctrine in
subject-matter eligibility analysis is significant to note because the PTAB’s
jurisprudence is often adopted or followed by courts.195
The Federal Circuit affirmed the PTAB’s use of the printed matter doctrine
in a § 101 analysis. In an appeal from the PTAB, the Federal Circuit, in In re Marco
Guldenaar Holding B.V., affirmed the rejection of a patent application for a method
of playing a dice game under § 101:
Because the only arguably unconventional aspect of the recited
method of playing a dice game is printed matter, which falls outside
the scope of § 101, the rejected claims do not recite an ‘inventive
190

An ex parte appeal is when an applicant appeals an examiner’s final rejection of her patent
application to the PTAB in hopes of getting a patent granted. Appeals, U.S. PATENT & TRADEMARK
OFFICE, https://www.uspto.gov/patents-application-process/patent-trial-and-appeal-board/appeals
(last visited Feb. 22, 2019).
191
Osenga, supra note 17, at 407.
192
For purposes of this Note, and as of January 2019, these fifteen cases are from a basic search
on Westlaw and is not a definitive or conclusive list.
193
See generally Ex parte Stone, No. 2017-010303, 2018 WL 6119991 (P.T.A.B. Oct. 30, 2018);
Ex parte Dorr, No. 2017-006607, 2018 WL5294811 (P.T.A.B. Oct. 11, 2018); Ex parte Wallace,
No. 2018-002391, 2018 WL 5043711 (P.T.A.B. Sept. 28, 2018); Ex parte Carrato, No. 2016007538, 2018 WL 3756657 (P.T.A.B. July 23, 2018); Ex parte Hellem, No. 2016-004724, 2018 WL
3586188 (P.T.A.B. July 10, 2018); Ex parte Irby, No. 2016-008533, 2018 WL 3425429 (P.T.A.B.
June 27, 2018); Ex parte Spooner, No. 2017-000514, 2018 WL 3425441 (P.T.A.B. June 27, 2018).
Notably, two separate cases cited and rejected patent claims under Praxair’s printed matter doctrine
as obvious under § 103 because the printed matter was directed to ineligible subjected matter. See
Ex parte Subha v. Raman, No. 2017-001873, 2018 WL 6338505 at *4 (P.T.A.B. Nov. 6, 2018); Ex
parte Multer, No. 2017-002353, 2018 WL 5631437 at *8–9 (P.T.A.B. Oct. 15, 2018).
194
See Ex parte Stone, 2018 WL 6119991 at *7–8; Ex parte Dorr, 2018 WL5294811 at*8–9; Ex
parte Wallace, 2018 WL 5043711 at *6 n.3; Ex parte Carrato, 2018 WL 3756657 at *4; Ex parte
Hellem, 2018 WL 3586188 at *7; Ex parte Irby, 2018 WL 3425429 at *5; Ex parte Spooner, 2018
WL 3425441 at *5.
195
See Osenga, supra note 17, at 409 (noting that “the PTAB’s jurisprudence is often adopted, or
at least followed, by the courts”).
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concept’ sufficient to ‘transform’ the claimed subject matter into a
patent-eligible application of the abstract idea.196
The Federal Circuit cited Praxair to invalidate the application’s claims under the
printed matter doctrine and § 101.197 The ruling in Marco affirmed the PTAB’s
heightened influence over the law of subject-matter eligibility and expanded the
scope of the Alice-Mayo two-step test to include the printed matter doctrine.
Ultimately, this creates another basis on which the PTAB may invalidate
applications and patents. Because of Praxair, USPTO examiners, the PTAB, and
courts are free to use the printed matter doctrine in the § 101 Alice-Mayo analysis.
Finally, if the PTAB invalidates more patents—like in Praxair—additional
biotechnology inventions could lose their patent rights. Some commentators refer
to the PTAB as “death squads killing property rights.”198 While in the past the
Federal Circuit acted as a “savior” by reversing the USPTO in certain
circumstances, it has recently been less inclined to save claims.199 The PTAB’s
power over § 101 could greatly affect biotechnology and bioscience industries by
making patent protection even more uncertain and unlikely than when the courts
had exclusive control.200 For example, when the PTAB invalidates patents in postgrant proceedings, it signals to the company involved, as well as other companies
in similar fields, that patent rights are uncertain or unlikely.201 Uncertainty in patent
rights will cause companies to change how they invest their research and
development money.202 A lack of investment in biotechnology research and
development could limit future advances in the field.203 Thus, while patent
protection for biotechnology inventions was already declining after the Mayo and
Myriad decisions, the PTAB’s decision in Praxair may have a significant impact
on patent rights and innovation in biotechnology industries.
196

In re Marco Guldenaar Holding B.V., 911 F.3d 1157, 1162 (Fed. Cir. 2018).
Id. at 1161 (“Claim limitations directed to the content of information and lacking a requisite
functional relationship are not entitled to patentable weight because such information is not patent
eligible subject matter under 35 U.S.C. § 101.”) (citing Praxair Distrib., Inc. v. Mallinckrodt Hosp.
Prods. IP Ltd., 890 F.3d 1024, 1032 (Fed. Cir. 2018)).
198
See generally Lefstin et al., supra note 4, at 589 (noting that with respect to the PTAB, “if a
patent applicant or owner takes a patent eligibility case . . . it is ‘not likely to end well.’”); Madigan
& Mossoff, supra note 11, at 952 (discussing that the PTAB is one of the “bleakest” venues for
patent owners); Rob Sterne & Gene Quinn, PTAB Death Squads: Are All Commercially Viable
Patents Invalid?, IPWATCHDOG (March 24, 2014), http://www.ipwatchdog.com/2014/03/24/ptabdeath-squads-are-all-commercially-viable-patents-invalid/id=48642 (discussing the unanticipated
low success rate of patent owners in PTAB proceedings).
199
Lefstin et al., supra note 4, at 589.
200
See id. at 584.
201
See Osenga, supra note 17, at 409.
202
See Madigan & Mossoff, supra note 11, at 946–47 (discussing how the current state of § 101
has caused a lot of legal uncertainty in the U.S. patent system which undermines universities, venture
capitalists, and companies making long-term investment decisions in research and development).
203
Lefstin et al., supra note 4, at 584.
197
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CONCLUSION
Praxair is the perfect example of how much influence the PTAB has over
§ 101. As a result of Praxair, the PTAB (1) expanded IPR’s scope and reach to
possibly allow petitioners to bring § 101 challenges, and (2) added more
uncertainty to subject-matter eligibility. Allowing the PTAB to invalidate patents
under the printed matter doctrine only made § 101 more unworkable and uncertain.
Praxair gives more power and discretion to the PTAB to determine patent subjectmatter eligibility under § 101.
What does this mean for future biotechnology research and development?
Property right protection, especially patent protection, drive biotechnology
innovation. The recent § 101 Supreme Court cases create legal uncertainty for
patent protection for future biotechnology inventions. Now adding the PTAB’s
impact on § 101, there is no telling what could happen to those patent rights. This
uncertainty could force investors to stop funding research in these industries, which
then could limit future advances in the field. Reports in the biotechnology fields
for software and technology, show developments in the subject matter eligibility
laws impact research and development.204 Research and development within the
biotechnology industries have been advancing with increasing speed. If the law
surrounding § 101 remains stagnant, then advancement in future biotechnology
innovation may be inhibited.

204

Id. at 582–85.

